vs
Celldex Therapeutics, Inc.（CLDX）与Lantheus Holdings, Inc.（LNTH）财务数据对比。点击上方公司名可切换其他公司
Lantheus Holdings, Inc.的季度营收约是Celldex Therapeutics, Inc.的3389.9倍（$406.8M vs $120.0K）。Lantheus Holdings, Inc.净利率更高（13.3% vs -67764.2%，领先67777.5%）。Lantheus Holdings, Inc.同比增速更快（4.0% vs -89.8%）。Lantheus Holdings, Inc.自由现金流更多（$81.4M vs $-65.2M）。过去两年Lantheus Holdings, Inc.的营收复合增速更高（4.9% vs -12.3%）
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
CLDX vs LNTH — 直观对比
营收规模更大
LNTH
是对方的3389.9倍
$120.0K
营收增速更快
LNTH
高出93.8%
-89.8%
净利率更高
LNTH
高出67777.5%
-67764.2%
自由现金流更多
LNTH
多$146.6M
$-65.2M
两年增速更快
LNTH
近两年复合增速
-12.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $120.0K | $406.8M |
| 净利润 | $-81.3M | $54.1M |
| 毛利率 | — | 59.2% |
| 营业利润率 | -72628.3% | 19.0% |
| 净利率 | -67764.2% | 13.3% |
| 营收同比 | -89.8% | 4.0% |
| 净利润同比 | -72.7% | 558.8% |
| 每股收益（稀释后） | $-1.23 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDXLNTH
| Q4 25 | $120.0K | $406.8M | ||
| Q3 25 | $0 | $384.0M | ||
| Q2 25 | $730.0K | $378.0M | ||
| Q1 25 | $695.0K | $372.8M | ||
| Q4 24 | $1.2M | $391.1M | ||
| Q3 24 | $3.2M | $378.7M | ||
| Q2 24 | $2.5M | $394.1M | ||
| Q1 24 | $156.0K | $370.0M |
净利润CLDXLNTH
| Q4 25 | $-81.3M | $54.1M | ||
| Q3 25 | $-67.0M | $27.8M | ||
| Q2 25 | $-56.6M | $78.8M | ||
| Q1 25 | $-53.8M | $72.9M | ||
| Q4 24 | $-47.1M | $-11.8M | ||
| Q3 24 | $-42.1M | $131.1M | ||
| Q2 24 | $-35.8M | $62.1M | ||
| Q1 24 | $-32.8M | $131.1M |
毛利率CLDXLNTH
| Q4 25 | — | 59.2% | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 63.8% | ||
| Q1 25 | — | 63.8% | ||
| Q4 24 | — | 63.5% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 65.4% |
营业利润率CLDXLNTH
| Q4 25 | -72628.3% | 19.0% | ||
| Q3 25 | — | 11.4% | ||
| Q2 25 | -8747.5% | 23.3% | ||
| Q1 25 | -9027.2% | 27.4% | ||
| Q4 24 | -4768.3% | 29.1% | ||
| Q3 24 | -1633.5% | 35.3% | ||
| Q2 24 | -1854.2% | 26.1% | ||
| Q1 24 | -26030.8% | 28.8% |
净利率CLDXLNTH
| Q4 25 | -67764.2% | 13.3% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | -7753.4% | 20.8% | ||
| Q1 25 | -7740.4% | 19.6% | ||
| Q4 24 | -4007.8% | -3.0% | ||
| Q3 24 | -1320.0% | 34.6% | ||
| Q2 24 | -1434.8% | 15.8% | ||
| Q1 24 | -21030.8% | 35.4% |
每股收益（稀释后）CLDXLNTH
| Q4 25 | $-1.23 | $0.86 | ||
| Q3 25 | $-1.01 | $0.41 | ||
| Q2 25 | $-0.85 | $1.12 | ||
| Q1 25 | $-0.81 | $1.02 | ||
| Q4 24 | $-0.71 | $-0.18 | ||
| Q3 24 | $-0.64 | $1.79 | ||
| Q2 24 | $-0.54 | $0.88 | ||
| Q1 24 | $-0.56 | $1.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $518.6M | $359.1M |
| 总债务越低越好 | — | $568.7M |
| 股东权益账面价值 | $527.2M | $1.1B |
| 总资产 | $583.0M | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资CLDXLNTH
| Q4 25 | $518.6M | $359.1M | ||
| Q3 25 | $583.2M | $382.0M | ||
| Q2 25 | $630.3M | $695.6M | ||
| Q1 25 | $673.3M | $938.5M | ||
| Q4 24 | $725.3M | $912.8M | ||
| Q3 24 | $756.0M | $866.4M | ||
| Q2 24 | $802.3M | $757.0M | ||
| Q1 24 | $823.8M | $718.3M |
总债务CLDXLNTH
| Q4 25 | — | $568.7M | ||
| Q3 25 | — | $567.9M | ||
| Q2 25 | — | $566.8M | ||
| Q1 25 | — | $566.1M | ||
| Q4 24 | — | $565.3M | ||
| Q3 24 | — | $613.0K | ||
| Q2 24 | — | $563.2M | ||
| Q1 24 | — | $562.5M |
股东权益CLDXLNTH
| Q4 25 | $527.2M | $1.1B | ||
| Q3 25 | $598.4M | $1.1B | ||
| Q2 25 | $655.4M | $1.2B | ||
| Q1 25 | $703.0M | $1.2B | ||
| Q4 24 | $747.0M | $1.1B | ||
| Q3 24 | $785.9M | $1.2B | ||
| Q2 24 | $813.7M | $1.0B | ||
| Q1 24 | $838.6M | $945.5M |
总资产CLDXLNTH
| Q4 25 | $583.0M | $2.2B | ||
| Q3 25 | $648.4M | $2.3B | ||
| Q2 25 | $692.4M | $2.1B | ||
| Q1 25 | $739.5M | $2.1B | ||
| Q4 24 | $792.3M | $2.0B | ||
| Q3 24 | $823.2M | $2.0B | ||
| Q2 24 | $845.6M | $1.9B | ||
| Q1 24 | $868.8M | $1.8B |
负债/权益比CLDXLNTH
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-63.9M | $90.2M |
| 自由现金流经营现金流 - 资本支出 | $-65.2M | $81.4M |
| 自由现金流率自由现金流/营收 | -54350.8% | 20.0% |
| 资本支出强度资本支出/营收 | 1067.5% | 2.2% |
| 现金转化率经营现金流/净利润 | — | 1.67× |
| 过去12个月自由现金流最近4个季度 | $-213.7M | $354.1M |
8季度趋势，按日历期对齐
经营现金流CLDXLNTH
| Q4 25 | $-63.9M | $90.2M | ||
| Q3 25 | $-48.6M | $105.3M | ||
| Q2 25 | $-44.0M | $87.1M | ||
| Q1 25 | $-54.4M | $107.6M | ||
| Q4 24 | $-32.5M | $157.7M | ||
| Q3 24 | $-55.3M | $175.1M | ||
| Q2 24 | $-29.3M | $84.7M | ||
| Q1 24 | $-40.6M | $127.2M |
自由现金流CLDXLNTH
| Q4 25 | $-65.2M | $81.4M | ||
| Q3 25 | $-49.1M | $94.7M | ||
| Q2 25 | $-44.7M | $79.1M | ||
| Q1 25 | $-54.6M | $98.8M | ||
| Q4 24 | $-33.2M | $141.4M | ||
| Q3 24 | $-55.9M | $159.3M | ||
| Q2 24 | $-29.6M | $73.5M | ||
| Q1 24 | $-41.0M | $119.0M |
自由现金流率CLDXLNTH
| Q4 25 | -54350.8% | 20.0% | ||
| Q3 25 | — | 24.7% | ||
| Q2 25 | -6127.8% | 20.9% | ||
| Q1 25 | -7861.4% | 26.5% | ||
| Q4 24 | -2828.3% | 36.1% | ||
| Q3 24 | -1751.2% | 42.0% | ||
| Q2 24 | -1185.0% | 18.7% | ||
| Q1 24 | -26270.5% | 32.2% |
资本支出强度CLDXLNTH
| Q4 25 | 1067.5% | 2.2% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | 99.7% | 2.1% | ||
| Q1 25 | 38.1% | 2.3% | ||
| Q4 24 | 64.3% | 4.2% | ||
| Q3 24 | 17.1% | 4.2% | ||
| Q2 24 | 11.0% | 2.8% | ||
| Q1 24 | 220.5% | 2.2% |
现金转化率CLDXLNTH
| Q4 25 | — | 1.67× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | 1.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLDX
暂无分部数据
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
